Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TTA-A2 是一种选择性 T 型钙通道拮抗剂,是一种有效的抗惊厥药,可减少孕烷 X 受体的激活。它对 Cav3.1 (a1G) 和 Cav3.2 (a1H) 通道在 -80 mV 和- 100 mV 保持电位上具有同样的作用,IC50 值分别为 89 和 92 nM。它可用于多种人类神经系统疾病的研究,包括睡眠障碍和癫痫。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,490 | 现货 | ||
5 mg | ¥ 3,160 | 现货 | ||
10 mg | ¥ 4,660 | 现货 | ||
25 mg | ¥ 7,390 | 现货 | ||
50 mg | ¥ 9,950 | 现货 | ||
100 mg | ¥ 13,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,460 | 现货 |
产品描述 | TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy. |
靶点活性 | Cav 3.2 (a1H):92 nM, Cav 3.1 (a1G):89 nM |
体内活性 | TTA-A2 (oral gavage; 10 mg/kg; once daily; 5 days) shows selective effect on recurrent thalamocortical network activity, it suppresses active wake and promotes slow-wave sleep in wild-type mice but not in mice lacking both Cav3.1 and Cav3.3[1].TTA-A2 (oral gavage;?3 mg/kg;?single dose) produces significant changes in sleep architecture in rats.?A reduction in active wake soon after dosing with a concurrent increase in delta sleep and decrease in REM sleep.?Additionally, these effects persists for up to 4 h post-dose in rats[2]. |
分子量 | 378.39 |
分子式 | C20H21F3N2O2 |
CAS No. | 953778-63-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.5 mg/mL (72.68 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6428 mL | 13.2139 mL | 26.4278 mL | 66.0694 mL |
5 mM | 0.5286 mL | 2.6428 mL | 5.2856 mL | 13.2139 mL | |
10 mM | 0.2643 mL | 1.3214 mL | 2.6428 mL | 6.6069 mL | |
20 mM | 0.1321 mL | 0.6607 mL | 1.3214 mL | 3.3035 mL | |
50 mM | 0.0529 mL | 0.2643 mL | 0.5286 mL | 1.3214 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TTA-A2 953778-63-7 Membrane transporter/Ion channel Metabolism Calcium Channel Pregnane X receptor neurological diseases T-type calcium channel Inhibitor Ca2+ channels Ca channels Electrocorticogram TTAA2 sleep disorders TTA-A-2 inhibit TTA A2 Epilepsy inhibitor